The global hemoglobinopathies market size is expected to reach USD 12.6 billion by 2026, according to a new report by Radiant Insights, Inc. It is projected to expand at a CAGR of 10.2% during the forecast period.
Rising prevalence of hemoglobin disorders such as Sickle Cell Disease (SCD), thalassemia, Hb C, and Hb E is estimated to be a high impact rendering driver for the market. According to the World Health Organization (WHO), hemoglobin disorders are endemic in over 60% of 229 countries affecting over 70% of births. It is also reported that minimum 5% of the world population are carriers of significant hemoglobin variation.
Download Free Sample Report @ https://www.radiantinsights.com/research/hemoglobinopathies-market/request-sample
Prevalence of hemoglobinopathies is high in low-income countries from regions, such as Sub-Saharan region and South-east Asia. 85% of the affected population in U.S. and Europe has ancestral base in these regions.
Governments are collaborating with local institutes to undertake awareness programs for curbing the effect of hemoglobinopathies-related mortality rate. For instance, Sickle Cell Disease Coalition (SCDC) was founded by The American Society of Hematology (ASH) in 2016 to promote awareness for the condition and enhance outcomes for individuals.
Insufficient healthcare infrastructure and low levels of disease diagnosis and treatments are some of the key factors contributing to the increase in target population in low-income regions such as South-east Asia, Mediterranean basin, and Africa.
North America led the overall hemoglobinopathies market in terms of revenue in 2018. Growing prevalence of blood disorders, favorable government programs, and high level of awareness among healthcare professionals and patients for hemoglobinopathies-related genetic testing, are the factors attributed to the growth.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to the presence of high unmet clinical needs, improving healthcare infrastructure, and rising economic levels. Moreover, introduction of low-cost diagnostic alternatives for hemoglobinopathies is likely to further boost the growth.
Further key findings from the report suggest:
• SCD segment held the largest market share in 2018 owing to rising prevalence of sickle cell disease and presence of strong product pipeline such as LentiGlobin
• Genetic testing for diagnosis of sickle cell disorders is expected to witness lucrative growth over the forecast period. Increasing awareness coupled with rising government programs is anticipated to enhance the usage rates for diagnostic tests pertaining to SCD
• Pre-implant genetic diagnosis is estimated to witness lucrative CAGR of over 8.0% during the forecast period owing to rising awareness levels among the population and increasing healthcare expenditure
• Blood transfusion was the largest therapy segment for hemoglobinopathies, owing to high acceptance of this treatment option and significant success rate
• Key market players include Gamida Cell; Alnylam Pharmaceuticals; Sanofi; Sangamo Therapeutics Inc.; Global Blood Therapeutics; bluebird bio Inc.; Emmaus Life Sciences Inc.; Prolong Pharmaceuticals; and Celgene Corporation
Browse Full Research Report with TOC @ https://www.radiantinsights.com/research/hemoglobinopathies-market
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market segmentation & scope
1.2. Market definition
1.3. Information procurement
1.3.1. Purchased database
1.3.2. Radiant Insights internal database
1.3.3. Secondary sources & third party perspectives
1.3.4. Primary research
1.4. Information analysis
1.4.1. Data analysis models
1.5. Market formulation & data visualization
1.6. Data validation & publishing
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Global Hemoglobinopathies Market Variables, Trends & Scope
3.1. Penetration & Growth Prospect Mapping
3.2. Epidemiology Assessment of Hemoglobinopathies
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.2. Market Restraint Analysis
3.4. Hemoglobinopathies Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier Power: Moderate
3.4.1.2. Buyer Power: Moderate
3.4.1.3. Substitution Threat: Low
3.4.1.4. Threat from new entrant: High
3.4.1.5. Competitive rivalry: High
3.5. PESTEL Analysis
3.5.1. Political Landscape
3.5.2. Environmental Landscape
3.5.3. Social Landscape
3.5.4. Technology Landscape
3.5.5. Legal Landscape
Chapter 4. Hemoglobinopathies Market: Type Estimates & Trend Analysis
4.1. Definitions & Scope
4.2. Type market share analysis, 2018 & 2026
4.3. Type Dashboard
4.4. Global Hemoglobinopathies Market, by Type, 2014 to 2026
4.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
4.6. Thalassemia
4.6.1. Thalassemia market, 2014 - 2026 (USD Million)
4.6.2. Alpha thalassemia
4.6.2.1. Alpha thalassemia market, 2014 - 2026 (USD Million)
4.6.3. Beta thalassemia
4.6.3.1. Beta thalassemia market, 2014 - 2026 (USD Million)
4.7. Sickle Cell Disease (SCD)
4.7.1. Sickle Cell Disease (SCD) market, 2014 - 2026 (USD Million)
4.8. Other Hb Variants
4.8.1. Other Hb Variants market, 2014 - 2026 (USD Million)
Continued…
Read all Reports of this category @ https://www.radiantinsights.com/catalog/pharmaceutical
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. It assists and facilitate organizations and individuals procure market research reports, helping them in the decisions making process. The Organization has a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Media Contact:
Company Name: Radiant Insights, Inc
Contact Person: Michelle Thoras
Phone: (415) 349-0054
Toll Free: 1-888-928-9744
Address: 201 Spear Street 1100, Suite 3036,
City: San Francisco; State: California; Country: United States
Email: [email protected]
Website: https://www.radiantinsights.com/
The global Hemoglobinopathies Market size is expected to value at USD 8.82 billion by 2022.
The hemoglobinopathies industry is subject to witness a substantial growth due to the growing prevalence of hemoglobinopathies, particularly in underdeveloped economies such as South East Asia, Middle East region, and Africa.
In addition, increasing number of high unmet needs for diagnosis and treatment of these disorders is expected to fuel the growth of hemoglobinopathies market over the next seven years.
Globally, the hemoglobinopathies industry is predicted to grow at higher CAGR in the forecast period, providing numerous opportunities for market players to invest for research and development in the market.Hemoglobinopathy is commonly known as a genetic defect, which results in abnormal structure of single globin chains of the hemoglobin molecule.
Hemoglobinopathies are hereditary or inherited single gene disorders.
However, lack of awareness among general population and lack availability of healthcare facilities in rural areas in developing economies are considered as major challenges for sustained market growth.
Hemoglobinopathies market is a group of disorder which is associated with the blood and usually affects the red blood cell.
Sickle cell anemia, thalassemias, hemoglobin C disease and hemoglobin S-C disease are some of the common hemoglobinopathies disease.
They are usually detected by test like routine red blood cell count, high performance liquid chromatography, hemoglobin isoelectric focusing etc.
They are usually inherited from single-gene disorders.Hemoglobinopathies market is expected to rise to an estimated value of USD 12.75 billion by 2026, registering a CAGR of 10.45% in the forecast period of 2019-2026.
High prevalence of hemoglobinopathies is the major factor for the growth of this market.Get Exclusive PDF Sample Copy of Hemoglobinopathies Market Report (Including Full TOC, List of Tables & Figures, Chart) athttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hemoglobinopathies-marketMarket Drivers and Restraints:Rising awareness about hemoglobinopathies among consumer is driving the market growthImprovement in healthcare infrastructure is driving the marketIncreasing blood cancer cases among population is driving the growth of this market.Favorable government programs related to hemoglobinopathies will propel the marketAvailability of diagnostics alternative of hemoglobinopathies will also restraint the market growthLack of proper diagnostics test will hamper the growth of this marketThe major players covered in the Hemoglobinopathies Market Few of the major competitors currently working in the global hemoglobinopathies market are Abbott, Bio-Rad Laboratories, Inc., Danaher, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Nexcelom Bioscience LLC, NIHON KOHDEN CORPORATION, PerkinElmer Inc., Siemens, Sysmex Corporation, Novartis AG, Medunik USA Inc, Emmaus Medical, Bristol-Myers Squibb Company, ApoPharma Inc, Alnylam Pharmaceuticals, Inc., Gamida Cell, Biogen, Acceleron Pharma, Inc, Sangamo Therapeutics, CELGENE CORPORATION..Major TOC Of The ReportChapter One: Hemoglobinopathies Market OverviewChapter Two: Manufacturers ProfilesChapter Three: Global Hemoglobinopathies Market Competition, by PlayersChapter Four: Global Hemoglobinopathies Market Size by RegionsChapter Five: North America Hemoglobinopathies Market Revenue by CountriesChapter Six: Europe Hemoglobinopathies Market Revenue by CountriesChapter Seven: Asia-Pacific Hemoglobinopathies Market Revenue by CountriesChapter Eight: South America Hemoglobinopathies Market Revenue by CountriesFind More Competitor in TOC with Profile Overview Share Growth Analysis @https://www.databridgemarketresearch.com/toc/?dbmr=global-hemoglobinopathies-marketKey Report HighlightsComprehensive pricing analysis based on different product types and regional segmentsMarket size data in terms of revenue and sales volumeDeep insights about regulatory and investment scenarios of the global Hemoglobinopathies Market Analysis of market effect factors and their impact on the forecast and outlook of the global Hemoglobinopathies Market The detailed assessment of the vendor landscape and leading companies to help understand the level of competition in the global Hemoglobinopathies Market A roadmap of growth opportunities available in the global Hemoglobinopathies Market with the identification of key factorsThe exhaustive analysis of various trends of the global Hemoglobinopathies Market to help identify market developmentsGet Full Report Instantly For Free At https://www.databridgemarketresearch.com/reports/global-hemoglobinopathies-marketKey Questions Answered in Report:What is the key to the Hemoglobinopathies Market?What will the Hemoglobinopathies Market Demand and what will be Growth?What are the latest opportunities for Hemoglobinopathies Market in the future?What are the strengths of the key players?About Us:Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches.
We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the marketContact:Data Bridge Market ResearchTel: +1-888-387-2818Email: [email protected] Related Reports@Fluorescent Antibody Test (FAT) MarketDental Lasers MarketCorneal Tomography Market
The detailed market intelligence report on the Hemoglobinopathies market applies the best of both primary and secondary research to weighs upon the competitive landscape and the prominent market players expected to dominate the Hemoglobinopathies market for the forecast period, 2019 - 2026.
A detailed evaluation of the major events such as acquisition and mergers, collaborations, product launches, new entrants, and technology advancements offer a complete overview of what the future of the Hemoglobinopathies market will be like in the years to come.Request For Free PDF Sample Of This Research Report At: https://www.reportsanddata.com/sample-enquiry-form/2165Key participants include Alnylam Pharmaceuticals, Gamida Cell, Biogen Idec, AcceleronPharma, Sangamo BioSciences, Anthera Pharmaceuticals, Global Blood Therapeutics, Geetix Pharmaceuticals, Mast Therapeutics, Prolong Pharmaceuticals, Emmaus Medical, Celgene Corporation, Invenux, Optinova Ab, and HemaQuest PharmaceuticalsScope of the Report:Based on the in-depth analysis the research also brings to light major facts pertaining to the vital aspects such as market share, size, and growth rate.
Deep dive into other aspects including the investment feasibility, demand and supply, import and export status, supply chain management and growth prospects narrates a lot about what the business environment will be like for the forecast period,2019 - 2026.
All the vital statistics in the report are explained with the help of resources such as tables, charts, and info graphics.Various research techniques are applied to produce data on competitors’ strategies; past, present and future sales and purchasing trends.
Business owners aiming to inspect the present consumer base and reaching the target audience will be able to leverage the demographic details derived from different regions, to infer dynamic market shifts.
Insights on where the Hemoglobinopathies market should be heading during the forecast years from 2019 to 2026.
Overview:Market Research Future (MRFR) recently revealed that the global hemoglobinopathies market is making significant progress from its previous valuation of USD 5800 million in 2018 and in the forecast period of 2019 to 2027, it could reach a 10.2% CAGR.
Get Request Free Sample @ https://www.marketresearchfuture.com/sample_request/8098 Segmentation:The global hemoglobinopathies market report has several segments like treatment, type, and end users.
By type, the global market for hemoglobinopathies can be segmented into sickle cell disease, thalassemia, and other Hb variant diseases.
This region would benefit from the presence of countries like the US and Canada in the northern part.
Their superlative infrastructure would help the market in ensuring decent growth.
Competitive Landscape:The global market for hemoglobinopathies depends on various strategic details launched by eminent players like Global Blood Therapeutics, Bluebird Bio Inc., Sanofi, Sangamo Therapeutics Inc., Prolong Pharmaceuticals, Emmaus Life Sciences Inc., Alnylam Pharmaceuticals, Gamida Cell, Celgene Corporation, Mast Therapeutics, HemaQuest Pharmaceuticals, Acceleron Pharma, and Invenux.
